Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity.
Ann CaversMatthias Christian KuglerYesim OzgulerArshed Fahad Al-ObeidiGülen HatemiBeatrix M UeberheideDidar UcarOlivier ManchesJohannes NowatzkyPublished in: Annals of the rheumatic diseases (2022)
at the cellular level and point to an HLA-B51-restricted process. Our findings suggest that variant ERAP1-Hap10 partakes in BD pathogenesis by generating HLA-B51-restricted peptides, causing a change in immunodominance of the ensuing CD8 T cell response.